Dec 9, 2015

Cerberus Capital Management Invests $105M in PaxVax

A new $105 million investment by Cerberus Capital Management helps PaxVax focus on growing its typhoid vaccine business and launching its oral cholera vaccine.


Dec 9, 2015

The Daily Startup: Vaccine Maker PaxVax Picks Up $105 Million

Cerberus Capital Management, a private-equity firm, invests $105 million in PaxVax to alleviate debt and allow the company to focus on the growth of its typhoid vaccine and launch its single-dose oral vaccine for cholera.


Nov 30, 2015

The New Vaccine Legend of Bern

With a well-educated workforce, strong business environment, and robust life science market, PaxVax Berna complements the company’s current goals and plan for growth.


Sep 1, 2015

Biotech in Switzerland – The Success Story of PaxVax

PaxVax acquires Crucell Switzerland and saves nearly 80 high-quality manufacturing jobs. Looking ahead, the company plans to increase the site’s production as it brings new vaccines to market.


Jan 15, 2015

PaxVax Ready to Strike M&A Deals that Prove Its Sales Model, CEO Says

To promote its typhoid vaccine, PaxVax uses a team of seven to target the Department of Defense, large integrated health networks, universities and large wholesalers and distributers to reach approximately 100,000 vaccinators.


Sep 3, 2014

The Most Influential People in Vaccines

Among CEOs, chief scientists, advocates and other nominees, Dr. Thomas Monath, PaxVax Chief Technology Officer, is named the second most influential person in vaccines by VaccineNation.


Jul 3, 2014

Cholera Vaccine Developer PaxVax Passes Key Test

When tested against patients given a placebo, the PaxVax oral vaccine for the treatment of cholera was effective both 10 and 90 days after vaccination.


May 19, 2014

Cholera Vaccine Test May Help Travelers

Rochester Clinical Research is among several U.S. sites testing the PaxVax cholera vaccine in preparation for FDA approval to market to Americans traveling to high-risk areas.


Dec 11, 2013

Love in the Time of Cholera Vaccine

PaxVax is changing the future for individuals who want to travel to areas affected with cholera, as its rapid-acting, single-dose oral vaccine enters Phase III clinical trials.


Oct 14, 2013

Government Shutdown Muffles Biotech Sector’s Stock Boom

As part of Phase III clinical trials, PaxVax is testing its cholera vaccine in healthy volunteers at three research hospitals in the U.S.


Sep 9, 2013

High ‘Cholera Sell’? Vouching for Paxvax’s Phase III Strategy

As PaxVax enters Phase III trials for the once-daily, oral cholera vaccine, BioWorld Today discusses the company’s priority review voucher and potential to be the first cholera vaccine approved for marketing in the U.S.


Jul 1, 2013

Pharm Exec’s 2013 Emerging Pharma Leaders

Nima Farzan, Executive Vice President and COO of PaxVax, is named one of Pharmaceutical Executive’s 2013 Emerging Pharma Leaders.


2 of 3123